[Therapeutic effect of combined treatment with Ara-A dauricine and Chinese herbs in chronic hepatitis B infection].
77 patients with chronic active or persistent hepatitis of type B proved by liver biopsy were divided into two groups. 39 cases were treated with Ara-A. dauricine and polysaccharide of pore umbellate as group I. 38 cases were treated with Ara-A, radix isatidis and radix salviae mitiorrhize as group II. By the end of 3 months in the course, the effective rates of ALT and AST were 68.6% and 68.4% in group I, 34.4% and 34.8% in group II. The rates of HBeAg from positive to negative were 35.9% and 39.5% in group I and II respectively. Follow up to 3 months after cessation of therapy, ALT level was normal in 55.6% of group I and 60% of group II: HBeAg was negative in 42.9% of group I and in 50% of group II. Follow up to 9 months after cessation of the treatment, ALT was normal in 56.3% of group I and in 62.5% of group II, HBeAg was negative in 37.5% of group I and in 60% of group II. These results show that dauricine and polysaccharide of pore umbellate did not strengthen the antiviral effect of Ara-A.
Fu
X X
XX
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006513:Hepatitis B e Antigens / Q000097:blood; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000627:therapeutic use*
D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens; D007546:Isoquinolines; D000410:Alanine Transaminase; D014740:Vidarabine